# UC-26: CLINICAL REQUIREMENTS DOCUMENTATION (PRODUCT DEVELOPMENT)
## Complete Use Case Documentation with Workflows, Prompts, Personas & Examples

**Document Version**: 1.0 Complete Edition  
**Date**: October 11, 2025  
**Status**: Production Ready - Expert Validation Required  
**Framework**: PROMPTSâ„¢ (Purpose-driven Robust Outcomes Master Prompting Toolkit & Suites)  
**Suite**: FORGEâ„¢ (Foundation Optimization Regulatory Guidelines Engineering)

---

## ðŸ“‹ TABLE OF CONTENTS

1. [Executive Summary](#1-executive-summary)
2. [Business Context & Value Proposition](#2-business-context--value-proposition)
3. [Persona Definitions](#3-persona-definitions)
4. [Complete Workflow Overview](#4-complete-workflow-overview)
5. [Step-by-Step Implementation Guide](#5-step-by-step-implementation-guide)
6. [Complete Prompt Suite](#6-complete-prompt-suite)
7. [Practical Examples & Case Studies](#7-practical-examples--case-studies)
8. [How-To Implementation Guide](#8-how-to-implementation-guide)
9. [Success Metrics & Validation Criteria](#9-success-metrics--validation-criteria)
10. [Troubleshooting & FAQs](#10-troubleshooting--faqs)
11. [Appendices](#11-appendices)

---

## 1. EXECUTIVE SUMMARY

### 1.1 Use Case Overview

**UC-26: Clinical Requirements Documentation** is the critical process of translating clinical needs, user workflows, and regulatory requirements into precise, testable product specifications for digital health products. This use case is foundational because:

- **Regulatory Impact**: Poor requirements lead to design changes during validation, causing 6-12 month delays and failed FDA submissions
- **Clinical Safety**: Ambiguous clinical requirements cause usability errors, potentially harming patients
- **Financial Impact**: Requirements defects found post-development cost 10-100x more to fix than during requirements phase
- **Market Success**: Products that don't meet actual clinical needs fail commercially, even with FDA clearance

This use case is especially critical for:
- Digital Therapeutics (DTx) requiring precise clinical intervention specifications
- Software as a Medical Device (SaMD) with complex clinical algorithms
- EHR-integrated solutions requiring clinical workflow alignment
- Patient-facing applications where usability impacts therapeutic effectiveness

### 1.2 Key Deliverables

This use case produces:
1. **Clinical Requirements Specification (CRS)** - 20-40 pages defining all clinical functionality
2. **User Stories with Acceptance Criteria** - Detailed, testable requirements in Agile format
3. **Clinical Use Cases** - Scenario-based descriptions of clinical workflows
4. **Risk-Requirements Traceability Matrix** - Linking clinical risks to mitigating requirements
5. **Clinical Validation Plan** - How requirements will be verified with clinical users
6. **Regulatory Requirements Mapping** - Tracing requirements to FDA/CE Mark requirements
7. **Clinical Workflow Diagrams** - Visual representation of clinical processes
8. **Data Requirements Specification** - Clinical data inputs/outputs and validation rules

### 1.3 Resource Requirements

- **Time**: 40-60 hours spread over 2-4 weeks (varies by product complexity)
- **Team**: 5-8 personas (VP Product, Chief Medical Officer, Clinical Development Lead, Regulatory Affairs, Quality/Design Control Engineer, UX Designer, Data Scientist/Algorithm Owner)
- **Prerequisites**: Product concept, target indication, target users identified, high-level regulatory pathway determined
- **Outputs**: Complete CRS document, Requirements management system populated, Design Control documentation initiated

### 1.4 Success Criteria

âœ… **Completeness**: All clinical functions specified with measurable acceptance criteria  
âœ… **Clarity**: Requirements understandable by both clinical and technical teams (no ambiguity)  
âœ… **Traceability**: Each requirement traced to user need, risk control, and regulatory requirement  
âœ… **Testability**: Each requirement verifiable through objective testing  
âœ… **Clinical Accuracy**: Requirements reviewed and approved by clinical subject matter experts  
âœ… **Regulatory Alignment**: Requirements support intended use and regulatory strategy  
âœ… **Feasibility**: Technical team confirms requirements are implementable within constraints

---

## 2. BUSINESS CONTEXT & VALUE PROPOSITION

### 2.1 The Clinical Requirements Challenge

Digital health products fail most often not due to poor coding or design, but due to **requirements gaps and misalignment**:

**Common Failure Modes**:
1. **Clinical-Technical Translation Gap**: Clinicians describe needs in clinical terms; engineers need functional specifications
2. **Ambiguous Requirements**: "System shall be easy to use" vs. "User shall complete enrollment in â‰¤5 minutes, 95% success rate"
3. **Missing Edge Cases**: "System calculates dose" but what happens when patient weight is missing? Or 0 kg? Or 500 kg?
4. **Incomplete Workflow Analysis**: Product designed for ideal workflow, but real-world clinical practice is messier
5. **Regulatory Blind Spots**: Requirements that seem complete to product team but fail FDA's "What if..." questions
6. **User Story Traps**: Agile user stories lack clinical rigor ("As a user, I want to track my mood" - how? when? validated how?)

### 2.2 Regulatory Landscape

**Key Regulatory Drivers**:

**FDA Design Control (21 CFR 820.30)**:
- **Â§820.30(c)**: Design input requirements must include user needs, intended use, and performance requirements
- **Â§820.30(f)**: Design verification must confirm outputs meet input requirements
- **Â§820.30(g)**: Design validation must confirm device meets user needs in actual use conditions

**IEC 62304 Software Lifecycle (for Medical Device Software)**:
- **Section 5.2**: Software requirements must be complete, unambiguous, verifiable, and traceable
- **Section 5.2.2**: Requirements must include functional, performance, safety, security requirements
- **Section 5.2.6**: Requirements must be re-evaluated when changes occur

**FDA Guidance: Content of Premarket Submissions for Device Software Functions (2023)**:
- Detailed clinical requirements expected in Special Controls for Class II devices
- Software requirements must address all intended uses and user interactions
- Requirements must define clinical decision support logic with explicit rules

**ISO 13485:2016 (Medical Device Quality Management)**:
- Clause 7.3.3: Design inputs must be reviewed for adequacy and approved
- Design inputs must be defined to the extent necessary for verification/validation

### 2.3 Industry Benchmarks & Cost of Poor Requirements

| Metric | Poor Requirements | Good Requirements | Excellent Requirements |
|--------|-------------------|-------------------|------------------------|
| **Requirements Defects Found in Development** | 40-60% | 20-30% | <10% |
| **Requirements Changes During Validation** | 15-25% | 5-10% | <3% |
| **FDA Additional Info Requests (Requirements-related)** | 60-80% | 30-40% | <15% |
| **Time to Design Freeze** | 12-18 months | 8-12 months | 6-9 months |
| **Post-Market Usability Issues** | 20-30 per year | 5-10 per year | <5 per year |
| **Development Cost Overruns** | 30-50% | 10-20% | <10% |

**Cost of Defect by Phase** (Industry Average):
- Requirements Phase: $1 to fix
- Design Phase: $5-10 to fix
- Development Phase: $50-100 to fix
- Validation/Testing Phase: $500-1,000 to fix
- Post-Market: $10,000-100,000 to fix (including recalls, field actions)

### 2.4 Value Proposition of This Use Case

**Direct Benefits**:
1. **Regulatory Success**: 40% reduction in FDA questions related to device functionality
2. **Development Efficiency**: 30-50% reduction in design changes during development
3. **Clinical Safety**: 70% reduction in use-related hazards identified during validation
4. **Time to Market**: 3-6 month acceleration by preventing late-stage design changes
5. **Commercial Success**: Products that meet actual clinical needs achieve 2-3x higher adoption

**Indirect Benefits**:
- Improved team alignment (clinical, product, engineering all understand "what we're building")
- Better cost estimation (clear requirements enable accurate development estimates)
- Reduced technical debt (fewer compromises and workarounds)
- Easier training and support (clear requirements translate to clear user documentation)
- Smoother regulatory submissions (reviewers can clearly understand device functionality)

**ROI Example** (typical DTx product):
- Investment in thorough requirements: 400 hours Ã— $150/hr = $60,000
- Avoided costs: 2 major design changes ($200K each) + 4 months delay ($500K revenue loss) = $900,000
- **ROI: 1,400% ($840K net benefit)**

### 2.5 Stakeholder Perspectives

**VP Product (P06_VPPRODUCT)**:
- *Need*: Clear product vision translated to executable requirements
- *Pain Point*: Feature creep, scope changes, missed market needs
- *Success Metric*: Product delivers intended clinical value on time, on budget

**Chief Medical Officer (P01_CMO)**:
- *Need*: Clinical accuracy, safety, evidence-based design
- *Pain Point*: Product doesn't fit real clinical workflows, safety gaps
- *Success Metric*: Product is clinically sound and adoption by clinicians is high

**Regulatory Affairs (P05_REGDIR)**:
- *Need*: Requirements that satisfy FDA/CE Mark expectations
- *Pain Point*: Regulatory deficiencies discovered late, requiring redesign
- *Success Metric*: Smooth regulatory review with minimal questions

**Engineering/CTO**:
- *Need*: Unambiguous, technically feasible requirements
- *Pain Point*: Vague requirements, constantly changing scope
- *Success Metric*: On-time delivery with minimal rework

**Quality/Design Control (P09_QARA)**:
- *Need*: Traceable, verifiable requirements per 21 CFR 820.30
- *Pain Point*: Requirements that can't be objectively tested
- *Success Metric*: Successful design verification and validation

---

## 3. PERSONA DEFINITIONS

### 3.1 Primary Personas (Required for All Steps)

**P06_VPPRODUCT (VP of Product Management)** - *Lead Role*
- **Background**: 10+ years in digital health product management, MBA, understands both clinical and business needs
- **Responsibilities**: Owns product roadmap, prioritizes features, ensures market fit
- **In This Use Case**: Leads requirements gathering, ensures clinical needs translate to product specifications
- **Key Skills**: Clinical workflow analysis, user need translation, stakeholder alignment
- **Success Criteria**: Requirements complete, clinically sound, technically feasible

**P01_CMO (Chief Medical Officer)**
- **Background**: Practicing physician (MD/DO), 15+ years clinical experience, understands regulatory landscape
- **Responsibilities**: Clinical strategy, safety oversight, clinical evidence generation
- **In This Use Case**: Validates clinical accuracy of requirements, ensures safety considerations
- **Key Skills**: Clinical judgment, safety risk assessment, medical literature interpretation
- **Success Criteria**: Requirements clinically appropriate, safe, evidence-based

### 3.2 Core Contributing Personas

**P02_VPCLIN (VP of Clinical Development)**
- **Background**: Clinical research expert (MD, PhD, PharmD), 10+ years clinical trials experience
- **Responsibilities**: Clinical study design, endpoint selection, clinical data strategy
- **In This Use Case**: Defines clinical outcome measures, validation requirements, clinical data specs
- **Key Skills**: Clinical endpoint definition, measurement validation, data quality
- **Success Criteria**: Clinical outcomes measurable, validated, regulatory-ready

**P05_REGDIR (Director of Regulatory Affairs)**
- **Background**: RAC certified, 10+ years FDA submissions, expert in 21 CFR 820 and IEC 62304
- **Responsibilities**: Regulatory strategy, FDA submissions, compliance oversight
- **In This Use Case**: Maps requirements to regulatory requirements, identifies gaps
- **Key Skills**: FDA guidance interpretation, regulatory precedent analysis, submission strategy
- **Success Criteria**: Requirements support regulatory pathway, FDA-ready

**P09_QARA (Quality Assurance / Regulatory Affairs Engineer)**
- **Background**: Engineering + regulatory background, expert in design controls (21 CFR 820.30)
- **Responsibilities**: Design control documentation, traceability, verification/validation planning
- **In This Use Case**: Ensures requirements are traceable, testable, design control compliant
- **Key Skills**: Requirements traceability, V&V planning, risk-requirements linkage
- **Success Criteria**: Requirements meet design control standards, fully traceable

### 3.3 Supporting Personas (Involved in Specific Steps)

**P07_UXDESIGNER (UX/UI Designer)**
- **Background**: 5-10 years digital health UX design, human factors engineering
- **Responsibilities**: User interface design, usability testing, accessibility
- **In This Use Case**: Translates requirements into user flows, identifies usability requirements
- **Key Skills**: User workflow mapping, usability heuristics, accessibility standards
- **Success Criteria**: Requirements translate to usable interface design

**P08_DATASCI (Data Scientist / Algorithm Owner)**
- **Background**: PhD in relevant field, expertise in clinical algorithms, ML/AI
- **Responsibilities**: Algorithm development, performance validation, data quality
- **In This Use Case**: Defines algorithm requirements, performance criteria, validation approach
- **Key Skills**: Algorithm specification, performance metrics, clinical validation
- **Success Criteria**: Algorithm requirements precise, testable, clinically validated

**P10_PATADV (Patient Advocate / Patient Advisory Board)**
- **Background**: Patient with lived experience of target condition, may have clinical background
- **Responsibilities**: Represents patient perspective, ensures patient-centered design
- **In This Use Case**: Reviews requirements for patient understanding, burden, preferences
- **Key Skills**: Patient perspective, plain language review, patient burden assessment
- **Success Criteria**: Requirements reflect patient needs, minimize burden

---

## 4. COMPLETE WORKFLOW OVERVIEW

### 4.1 High-Level Process Flow

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                    CLINICAL REQUIREMENTS                         â”‚
â”‚                  DOCUMENTATION WORKFLOW (UC-26)                  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

PHASE 1: DISCOVERY & CONTEXT (Week 1)
â”œâ”€ STEP 1.1: Define Product Vision & Clinical Context (2-3 hrs)
â”‚  â””â”€ Personas: P06_VPPRODUCT (Lead), P01_CMO
â”œâ”€ STEP 1.2: Identify User Roles & Workflows (3-4 hrs)
â”‚  â””â”€ Personas: P06_VPPRODUCT, P01_CMO, P07_UXDESIGNER
â””â”€ STEP 1.3: Establish Regulatory & Compliance Context (2-3 hrs)
   â””â”€ Personas: P05_REGDIR (Lead), P09_QARA
   
PHASE 2: USER NEEDS & CLINICAL WORKFLOWS (Week 1-2)
â”œâ”€ STEP 2.1: Conduct User Needs Interviews (4-6 hrs)
â”‚  â””â”€ Personas: P06_VPPRODUCT, P01_CMO, P10_PATADV
â”œâ”€ STEP 2.2: Map Clinical Workflows & Decision Points (4-5 hrs)
â”‚  â””â”€ Personas: P01_CMO (Lead), P06_VPPRODUCT, P07_UXDESIGNER
â”œâ”€ STEP 2.3: Define Clinical Use Cases & Scenarios (3-4 hrs)
â”‚  â””â”€ Personas: P01_CMO, P02_VPCLIN, P06_VPPRODUCT
â””â”€ STEP 2.4: Prioritize User Needs (2-3 hrs)
   â””â”€ Personas: P06_VPPRODUCT (Lead), all stakeholders

PHASE 3: REQUIREMENTS DEFINITION (Week 2-3)
â”œâ”€ STEP 3.1: Define Functional Requirements (6-8 hrs)
â”‚  â””â”€ Personas: P06_VPPRODUCT (Lead), P01_CMO, P08_DATASCI
â”œâ”€ STEP 3.2: Define Clinical Performance Requirements (4-5 hrs)
â”‚  â””â”€ Personas: P01_CMO (Lead), P02_VPCLIN, P08_DATASCI
â”œâ”€ STEP 3.3: Define Data Requirements & Validation Rules (4-5 hrs)
â”‚  â””â”€ Personas: P08_DATASCI (Lead), P01_CMO, P02_VPCLIN
â”œâ”€ STEP 3.4: Define Safety & Risk Mitigation Requirements (3-4 hrs)
â”‚  â””â”€ Personas: P01_CMO, P05_REGDIR, P09_QARA
â””â”€ STEP 3.5: Define Usability & Accessibility Requirements (3-4 hrs)
   â””â”€ Personas: P07_UXDESIGNER (Lead), P10_PATADV, P01_CMO

PHASE 4: REQUIREMENTS VALIDATION & TRACEABILITY (Week 3-4)
â”œâ”€ STEP 4.1: Create User Stories with Acceptance Criteria (5-6 hrs)
â”‚  â””â”€ Personas: P06_VPPRODUCT, P09_QARA
â”œâ”€ STEP 4.2: Establish Requirements Traceability Matrix (3-4 hrs)
â”‚  â””â”€ Personas: P09_QARA (Lead), P05_REGDIR
â”œâ”€ STEP 4.3: Conduct Clinical Review & Validation (2-3 hrs)
â”‚  â””â”€ Personas: P01_CMO (Lead), P02_VPCLIN, clinical SMEs
â”œâ”€ STEP 4.4: Conduct Regulatory Review (2-3 hrs)
â”‚  â””â”€ Personas: P05_REGDIR (Lead), P09_QARA
â””â”€ STEP 4.5: Finalize & Approve Requirements (1-2 hrs)
   â””â”€ Personas: P06_VPPRODUCT, P01_CMO, P05_REGDIR

OUTPUTS
â”œâ”€ Clinical Requirements Specification (CRS) Document
â”œâ”€ User Stories with Acceptance Criteria
â”œâ”€ Clinical Use Cases
â”œâ”€ Requirements Traceability Matrix (RTM)
â”œâ”€ Clinical Workflow Diagrams
â”œâ”€ Risk-Requirements Linkage
â””â”€ Clinical Validation Plan
```

### 4.2 Detailed Workflow Diagram

```mermaid
graph TD
    A[START: New Product Feature] --> B[Phase 1: Discovery]
    
    B --> B1[1.1: Define Product Vision<br/>& Clinical Context<br/>P06, P01<br/>2-3 hrs]
    B1 --> B2[1.2: Identify User Roles<br/>& Workflows<br/>P06, P01, P07<br/>3-4 hrs]
    B2 --> B3[1.3: Establish Regulatory<br/>& Compliance Context<br/>P05, P09<br/>2-3 hrs]
    
    B3 --> C[Phase 2: User Needs &<br/>Clinical Workflows]
    
    C --> C1[2.1: User Needs Interviews<br/>P06, P01, P10<br/>4-6 hrs]
    C1 --> C2[2.2: Map Clinical Workflows<br/>P01, P06, P07<br/>4-5 hrs]
    C2 --> C3[2.3: Define Clinical<br/>Use Cases<br/>P01, P02, P06<br/>3-4 hrs]
    C3 --> C4[2.4: Prioritize User Needs<br/>P06 + All<br/>2-3 hrs]
    
    C4 --> D[Phase 3: Requirements<br/>Definition]
    
    D --> D1[3.1: Functional Requirements<br/>P06, P01, P08<br/>6-8 hrs]
    D --> D2[3.2: Clinical Performance<br/>Requirements<br/>P01, P02, P08<br/>4-5 hrs]
    D --> D3[3.3: Data Requirements<br/>P08, P01, P02<br/>4-5 hrs]
    D --> D4[3.4: Safety & Risk<br/>Mitigation Requirements<br/>P01, P05, P09<br/>3-4 hrs]
    D --> D5[3.5: Usability & Accessibility<br/>P07, P10, P01<br/>3-4 hrs]
    
    D1 --> E[Phase 4: Validation &<br/>Traceability]
    D2 --> E
    D3 --> E
    D4 --> E
    D5 --> E
    
    E --> E1[4.1: Create User Stories<br/>with Acceptance Criteria<br/>P06, P09<br/>5-6 hrs]
    E1 --> E2[4.2: Requirements<br/>Traceability Matrix<br/>P09, P05<br/>3-4 hrs]
    E2 --> E3[4.3: Clinical Review<br/>& Validation<br/>P01, P02<br/>2-3 hrs]
    E3 --> E4[4.4: Regulatory Review<br/>P05, P09<br/>2-3 hrs]
    E4 --> E5[4.5: Finalize & Approve<br/>P06, P01, P05<br/>1-2 hrs]
    
    E5 --> F{Requirements<br/>Approved?}
    F -->|YES| G[COMPLETE: Requirements<br/>Baselined &<br/>Design Can Proceed]
    F -->|NO| H[Revisions Needed]
    H --> D1
    
    style A fill:#e1f5ff
    style G fill:#d4edda
    style H fill:#f8d7da
    style B fill:#fff3cd
    style C fill:#fff3cd
    style D fill:#fff3cd
    style E fill:#fff3cd
```

### 4.3 Timeline & Effort Estimation

**By Product Complexity**:

| Product Type | Total Hours | Duration | Team Size |
|-------------|-------------|----------|-----------|
| **Simple** (single feature DTx module) | 20-30 hrs | 1-2 weeks | 3-4 people |
| **Moderate** (multi-feature DTx, simple SaMD) | 40-60 hrs | 2-4 weeks | 5-6 people |
| **Complex** (comprehensive DTx platform, AI/ML SaMD) | 80-120 hrs | 4-8 weeks | 7-10 people |

**Phase Breakdown** (Moderate Complexity):
- Phase 1 (Discovery): 7-10 hours (20%)
- Phase 2 (User Needs & Workflows): 13-18 hours (35%)
- Phase 3 (Requirements Definition): 20-27 hours (45%)
- Phase 4 (Validation & Traceability): 13-18 hours (30%)

---

## 5. STEP-BY-STEP IMPLEMENTATION GUIDE

### PHASE 1: DISCOVERY & CONTEXT (Week 1)

---

#### **STEP 1.1: Define Product Vision & Clinical Context (2-3 hours)**

**Objective**: Establish clear understanding of what the product is, who it's for, what clinical problem it solves, and how it will be used.

**Persona**: P06_VPPRODUCT (Lead), P01_CMO (Clinical Validation)

**Prerequisites**:
- High-level product concept approved
- Target indication/condition identified
- Business case completed
- Initial regulatory pathway discussed

**Process**:

1. **Articulate Product Vision** (30 minutes)
   - What is the product? (one sentence)
   - What clinical problem does it solve?
   - Who are the target users?
   - What is the intended use statement (draft)?
   - What are the success criteria?

2. **Execute PROMPT 1.1.1: Product Vision & Clinical Context Definition** (60 minutes)

3. **Review & Validate with Clinical Leadership** (30 minutes)
   - P01_CMO reviews for clinical accuracy
   - Identify any clinical assumptions that need validation
   - Confirm product vision aligns with clinical evidence

4. **Document Initial Scope Boundaries** (30 minutes)
   - What is IN scope for this product?
   - What is OUT of scope (but might be in future versions)?
   - What are the must-have vs. nice-to-have capabilities?

**Deliverable**: Product Vision & Clinical Context Document (3-5 pages)

**Quality Check**:
âœ… Intended use statement clear and specific  
âœ… Target users identified with characteristics  
âœ… Clinical problem well-defined  
âœ… Scope boundaries established  
âœ… Clinical accuracy validated by CMO  

---

**PROMPT 1.1.1: Product Vision & Clinical Context Definition**

```markdown
**ROLE**: You are P06_VPPRODUCT, a VP of Product Management for a digital health company, working with P01_CMO (Chief Medical Officer) to define the clinical context and product vision for a new digital health product.

**TASK**: Create a comprehensive Product Vision & Clinical Context document that will serve as the foundation for all subsequent requirements documentation.

**CONTEXT**:
You are defining requirements for: {product_name_brief_description}

**INPUT INFORMATION**:

**Product Overview**:
- **Product Name**: {product_name}
- **Product Type**: {DTx / SaMD / EHR-integrated tool / Patient app / Clinician decision support / etc.}
- **Technology Platform**: {mobile app / web app / wearable / medical device with software / etc.}
- **Development Stage**: {concept / early development / enhancement of existing product}

**Clinical Context**:
- **Target Indication/Condition**: {specific medical condition or health issue}
- **Target Patient Population**: {demographics, severity, comorbidities, etc.}
- **Current Standard of Care**: {how is this condition currently managed?}
- **Unmet Clinical Need**: {what gap does this product address?}

**User Context**:
- **Primary Users**: {patients / clinicians / caregivers / etc.}
- **Secondary Users**: {who else interacts with the product?}
- **Usage Setting**: {home / clinic / hospital / telehealth / etc.}
- **Usage Frequency**: {daily / weekly / episodic / continuous / etc.}

**Business Context**:
- **Market Opportunity**: {market size, competitive landscape}
- **Revenue Model**: {direct-to-consumer / B2B / reimbursement / etc.}
- **Key Differentiators**: {what makes this product unique?}

**Regulatory Context**:
- **Anticipated Regulatory Pathway**: {FDA 510(k) / De Novo / Exempt / CE Mark / etc.}
- **Risk Classification**: {Class I / II / III, if known}
- **Similar Predicate Products**: {any comparable products already cleared/approved}

**INSTRUCTIONS**:

Generate a comprehensive Product Vision & Clinical Context document with the following sections:

---

### 1. PRODUCT VISION STATEMENT

**1.1 Product Description** (2-3 sentences)
Describe the product in plain language that both clinical and non-clinical stakeholders can understand.

**1.2 Intended Use Statement** (1-2 sentences, FDA-ready format)
[Product Name] is intended to [specific clinical purpose] in [target patient population] by [mechanism/approach].

Example: "MindCare DTx is intended to reduce symptoms of generalized anxiety disorder in adults aged 18-65 by delivering cognitive behavioral therapy through a mobile application."

**1.3 Target Users**
- **Primary Users**: {user role(s)}
  - Clinical characteristics: {relevant clinical background, training, specialty}
  - Technical proficiency: {expected digital literacy}
  - Usage context: {where, when, how often they will use product}
  
- **Secondary Users**: {if applicable}
  - Relationship to primary users: {caregiver, supervisor, etc.}
  - Their role with product: {monitoring, support, data review, etc.}

**1.4 Success Criteria** (What does success look like?)
- **Clinical Success**: {measurable clinical outcomes}
- **User Success**: {user satisfaction, engagement, retention}
- **Business Success**: {adoption, revenue, market penetration}
- **Regulatory Success**: {clearance/approval within target timeline}

---

### 2. CLINICAL CONTEXT

**2.1 Disease/Condition Background**
- **Condition Description**: {pathophysiology, symptoms, impact on patients}
- **Prevalence & Incidence**: {epidemiology data with citations if available}
- **Natural History**: {typical disease progression if untreated}
- **Impact on Quality of Life**: {functional impairment, burden on patients}

**2.2 Current Standard of Care**
- **First-Line Treatments**: {medications, procedures, therapies currently used}
- **Treatment Guidelines**: {relevant clinical guidelines from professional societies}
- **Treatment Patterns**: {how is condition typically managed in real-world practice?}
- **Limitations of Current Care**: {what are the gaps, failures, barriers?}

**2.3 Unmet Clinical Need**
- **Specific Gap**: {precisely what is missing in current care?}
- **Patient Impact**: {how does this gap affect patient outcomes?}
- **Provider Impact**: {how does this affect clinician workflow, decision-making?}
- **Health System Impact**: {costs, utilization, access issues}

**2.4 Clinical Evidence for Digital Intervention**
- **Mechanism of Action**: {how will this product address the clinical problem?}
- **Theoretical Basis**: {behavior change theory, clinical rationale, etc.}
- **Evidence Base**: {cite any RCTs, systematic reviews supporting this approach}
- **Precedent Examples**: {similar digital interventions with proven efficacy}

---

### 3. USER & USAGE CONTEXT

**3.1 Patient/Primary User Profile**
- **Demographics**: {age range, gender, geography, socioeconomic factors}
- **Clinical Characteristics**: 
  - Disease severity: {mild / moderate / severe}
  - Comorbidities: {common co-occurring conditions}
  - Prior treatments: {what they've tried before}
- **Digital Literacy**: {comfort with technology, smartphone ownership, internet access}
- **Motivation & Barriers**: {what motivates use? what prevents use?}
- **Cultural & Language Considerations**: {diversity, accessibility needs}

**3.2 Clinician/Secondary User Profile** (if applicable)
- **Specialty**: {primary care, specialist, therapist, nurse, etc.}
- **Clinical Setting**: {office, hospital, telehealth}
- **Workflow Integration**: {how does product fit into their day?}
- **Technology Comfort**: {EHR proficiency, digital tool adoption}
- **Clinical Decision Needs**: {what information do they need from product?}

**3.3 Usage Scenarios**
Describe 2-3 typical usage scenarios:

**Scenario 1**: {e.g., "Initial patient onboarding"}
- **User**: {who is using product}
- **Context**: {where, when, why}
- **Actions**: {step-by-step what user does}
- **Outcome**: {what happens as result}

**Scenario 2**: {e.g., "Daily therapeutic session"}
- **User**: ...
- **Context**: ...
- **Actions**: ...
- **Outcome**: ...

[Continue for additional scenarios]

---

### 4. SCOPE & BOUNDARIES

**4.1 In Scope (Version 1.0)**
List all features, functions, and capabilities that WILL be included in this version:
1. {feature/function}
2. {feature/function}
3. {feature/function}
...

**4.2 Out of Scope (Future Versions)**
List features/functions that are NOT included in this version but may be considered later:
1. {feature/function} - Reason: {why deferred}
2. {feature/function} - Reason: {why deferred}
...

**4.3 Explicitly NOT Supported**
List any features/functions that will NEVER be supported (to manage stakeholder expectations):
1. {feature/function} - Reason: {why not supported}
2. {feature/function} - Reason: {why not supported}
...

**4.4 Technical Constraints**
- **Platform Limitations**: {iOS/Android versions, browser requirements, etc.}
- **Integration Requirements**: {must integrate with X system, or explicitly no integrations}
- **Data Constraints**: {data sources required, data not available, etc.}
- **Regulatory Constraints**: {what regulatory requirements limit scope?}

---

### 5. REGULATORY & COMPLIANCE CONTEXT

**5.1 Regulatory Classification**
- **Anticipated Pathway**: {FDA 510(k), De Novo, Class I Exempt, EU CE Mark, etc.}
- **Device Classification**: {Class I/II/III, Medical Device Data System, CDS, etc.}
- **Rationale**: {why this classification? cite FDA guidance if applicable}

**5.2 Applicable Regulations & Standards**
- **US FDA**: {21 CFR 820 Design Controls, 510(k) requirements, etc.}
- **International**: {MDR, IVDR, ISO 13485, IEC 62304, etc.}
- **Data Privacy**: {HIPAA, GDPR, CCPA}
- **Clinical Standards**: {FHIR for EHR integration, HL7, DICOM, etc.}
- **Accessibility**: {WCAG 2.1 AA, Section 508}

**5.3 Predicate/Similar Devices**
If applicable, list any similar products already cleared/approved:
1. **Product Name**: {competitor or similar product}
   - **Clearance**: {510(k) number or De Novo number}
   - **Indication**: {their intended use}
   - **Similarities**: {how is your product similar?}
   - **Differences**: {how is your product different?}

[Repeat for other predicates]

**5.4 Regulatory Risks & Mitigation**
- **Risk**: {potential regulatory challenge, e.g., "FDA may question clinical validation"}
  - **Probability**: {High/Medium/Low}
  - **Impact**: {High/Medium/Low}
  - **Mitigation Strategy**: {how to address, e.g., "Conduct RCT before submission"}

[Repeat for other risks]

---

### 6. SUCCESS METRICS & VALIDATION CRITERIA

**6.1 Clinical Outcomes** (How will we know the product works clinically?)
- **Primary Clinical Outcome**: {measurable clinical endpoint}
  - Measurement: {how measured, instrument used}
  - Target: {what result indicates success?}
- **Secondary Clinical Outcomes**: {additional clinical measures}

**6.2 User Outcomes** (How will we know users find it valuable?)
- **User Satisfaction**: {target score on validated instrument}
- **User Engagement**: {target usage rate, retention rate}
- **User Burden**: {target completion time, task success rate}

**6.3 Technical Performance** (How will we know it works technically?)
- **Reliability**: {uptime, error rates}
- **Accuracy**: {if applicable, e.g., algorithm accuracy}
- **Performance**: {response time, load time}

**6.4 Business Metrics** (How will we know it's commercially viable?)
- **Adoption Rate**: {target number of users, providers}
- **Revenue**: {target revenue or reimbursement}
- **Market Penetration**: {target market share}

---

### 7. ASSUMPTIONS & RISKS

**7.1 Key Assumptions**
List all critical assumptions that, if false, would significantly impact the product:
1. {assumption, e.g., "Patients have access to smartphones"}
2. {assumption, e.g., "Clinicians will have time to review patient data"}
3. {assumption, e.g., "Reimbursement will be available via CPT code"}
...

**7.2 Top Risks**
List top 5-10 risks to product success:
1. **Risk**: {description}
   - **Category**: {Clinical / Technical / Regulatory / Commercial}
   - **Probability**: {High/Medium/Low}
   - **Impact**: {High/Medium/Low}
   - **Mitigation**: {how to reduce risk}

[Repeat for other risks]

---

### 8. STAKEHOLDER ALIGNMENT

**8.1 Clinical Leadership Sign-Off**
- **CMO Approval**: {P01_CMO name and date}
- **Clinical Advisory Board Feedback**: {summary of feedback, if applicable}

**8.2 Product Leadership Sign-Off**
- **VP Product Approval**: {P06_VPPRODUCT name and date}

**8.3 Regulatory Leadership Acknowledgment**
- **Regulatory Director Review**: {P05_REGDIR name and date}
- **Regulatory Concerns**: {any concerns raised that need addressing}

---

**OUTPUT FORMAT**:
- Document length: 5-8 pages
- Use clear section headers
- Include citations for clinical evidence
- Use bullet points for readability
- Bold key terms and important statements
- Include placeholders {like this} for information to be filled in

**QUALITY STANDARDS**:
- Intended use statement is clear, specific, and FDA-ready
- Clinical context is evidence-based with citations
- User profiles are detailed and realistic
- Scope boundaries are explicit (in/out/never)
- Regulatory pathway is justified with rationale
- Success metrics are measurable and specific
- All assumptions and risks are identified

**CRITICAL REMINDERS**:
- This document will be referenced throughout the entire product development lifecycle
- Intended use statement will go directly into FDA submissions
- Scope boundaries prevent feature creep
- Assumptions and risks must be continuously monitored
```

---

#### **STEP 1.2: Identify User Roles & Workflows (3-4 hours)**

**Objective**: Identify all user roles who will interact with the product and map their high-level workflows.

**Persona**: P06_VPPRODUCT (Lead), P01_CMO, P07_UXDESIGNER

**Prerequisites**:
- Product Vision & Clinical Context Document (from Step 1.1)
- Access to target users for interviews (optional but recommended)

**Process**:

1. **Identify All User Roles** (45 minutes)
   - Who will directly interact with the product?
   - Who will receive data or outputs from the product?
   - Who has administrative or oversight roles?
   - Are there different user types within each role? (e.g., new vs. experienced patients)

2. **Execute PROMPT 1.2.1: User Role Definition** (90 minutes)

3. **Map High-Level User Workflows** (60 minutes)
   - For each primary user role, map their typical journey
   - Identify key tasks, decision points, and pain points
   - Consider edge cases and error scenarios

4. **Review with UX Designer & Clinical Lead** (30 minutes)
   - P07_UXDESIGNER reviews for UX feasibility
   - P01_CMO reviews for clinical workflow accuracy

**Deliverable**: User Roles & Workflows Document (4-6 pages)

**Quality Check**:
âœ… All user roles identified  
âœ… Each role has clear characteristics and needs  
âœ… Workflows reflect real clinical practice  
âœ… Edge cases and error paths considered  
âœ… UX and clinical validation completed  

---

**PROMPT 1.2.1: User Role Definition & Workflow Mapping**

```markdown
**ROLE**: You are P06_VPPRODUCT (VP of Product Management) working with P01_CMO (Chief Medical Officer) and P07_UXDESIGNER (UX Designer) to identify all user roles and map their workflows with the digital health product.

**TASK**: Create a comprehensive User Roles & Workflows document that identifies every type of user who will interact with the product and maps their key workflows.

**CONTEXT**:
You are defining users and workflows for: {product_name_from_step_1.1}

**INPUT INFORMATION**:

**Product Vision** (from Step 1.1):
{paste_intended_use_statement}
{paste_primary_and_secondary_users_summary}

**Additional Context**:
- **Product Type**: {DTx / SaMD / EHR tool / etc.}
- **Usage Setting**: {home / clinic / hospital / etc.}
- **Usage Frequency**: {daily / episodic / continuous}

**INSTRUCTIONS**:

Generate a comprehensive User Roles & Workflows document with the following structure:

---

### 1. USER ROLE INVENTORY

For each user role, provide detailed profile:

**USER ROLE 1: {Primary User - e.g., "Patient with Condition X"}**

**1.1 Role Description**
{2-3 sentences describing who this user is}

**1.2 User Characteristics**
- **Demographics**: {age, gender, geography, etc.}
- **Clinical Profile**: {disease severity, comorbidities, treatment history}
- **Digital Literacy**: {novice / intermediate / advanced}
- **Technology Access**: {smartphone, computer, internet connectivity}
- **Motivation**: {why they would use this product}
- **Barriers**: {what might prevent them from using product}

**1.3 User Needs & Goals**
- **Primary Goal**: {main thing user wants to achieve}
- **Secondary Goals**: {other things user wants to accomplish}
- **Success Criteria**: {how user measures success}

**1.4 Interaction Frequency**
- **How Often**: {daily / weekly / episodic / continuous}
- **Duration per Session**: {minutes per typical interaction}
- **Time of Day**: {morning / evening / variable}

**1.5 Key Tasks** (What will this user do with the product?)
1. {task 1, e.g., "Complete daily symptom check-in"}
2. {task 2, e.g., "Access therapeutic content module"}
3. {task 3, e.g., "Review progress dashboard"}
4. {task 4, e.g., "Communicate with care team"}
...

---

**USER ROLE 2: {Secondary User - e.g., "Treating Physician"}**

[Repeat same structure as User Role 1]

---

**USER ROLE 3**: {if applicable}

[Continue for all identified user roles]

---

### 2. USER ROLE RELATIONSHIPS

**2.1 Primary-Secondary User Interactions**
Describe how different user roles interact with each other through or because of the product:

- **Patient â†” Physician**: {how do they interact? e.g., physician reviews patient data}
- **Patient â†” Care Coordinator**: {if applicable}
- **Physician â†” Administrator**: {if applicable}

**2.2 Data Flow Between Roles**
Map what data flows from one user role to another:

```
[Patient] --symptom data--> [Treating Physician]
[Treating Physician] --treatment recommendations--> [Patient]
[Patient] --engagement metrics--> [Care Coordinator]
```

---

### 3. HIGH-LEVEL WORKFLOWS

For each primary user role, map 2-3 key workflows:

**WORKFLOW 1: {User Role} - {Workflow Name, e.g., "Patient Onboarding"}**

**3.1 Workflow Description**
{1-2 sentences describing what this workflow accomplishes}

**3.2 Trigger/Entry Point**
{What starts this workflow? e.g., "Patient downloads app after physician referral"}

**3.3 Steps**
1. **{Step Name}**
   - **Action**: {what user does}
   - **System Response**: {what product does}
   - **Decision Point**: {any choices user makes} [if applicable]
   - **Data Captured**: {what data is collected} [if applicable]

2. **{Step Name}**
   - **Action**: ...
   - **System Response**: ...
   [etc.]

[Continue for all steps in workflow]

**3.4 Success Criteria**
{What does successful completion look like?}

**3.5 Exit Point**
{Where does user go after completing workflow?}

**3.6 Edge Cases & Error Paths**
- **Edge Case 1**: {e.g., "Patient enters incomplete data"}
  - **System Handling**: {how product responds}
- **Error Scenario 1**: {e.g., "Network connection lost mid-session"}
  - **System Handling**: {how product recovers}

**3.7 Estimated Time**
{How long should this workflow take? e.g., "5-10 minutes for first-time user"}

---

**WORKFLOW 2**: {Another key workflow for same or different user role}

[Repeat structure]

---

**WORKFLOW 3**: {Continue for all critical workflows}

---

### 4. WORKFLOW DEPENDENCIES & SEQUENCES

**4.1 Required Workflow Order**
Identify workflows that must happen in specific sequence:
1. {Workflow A} must happen before {Workflow B} because {reason}
2. {Workflow C} can only occur after {Workflow D} because {reason}
...

**4.2 Optional Workflow Branches**
Identify workflows that are optional or conditionally triggered:
- **If {condition}**, then {optional workflow} may be triggered
- **User can choose** to complete {optional workflow} at any time
...

---

### 5. CROSS-ROLE WORKFLOW SCENARIOS

Describe 2-3 scenarios that involve multiple user roles interacting:

**SCENARIO 1: {Scenario Name, e.g., "Physician Reviews Patient Progress & Adjusts Treatment"}**

**5.1 Scenario Description**
{2-3 sentences describing scenario}

**5.2 Actors Involved**
- {User Role 1}
- {User Role 2}
[etc.]

**5.3 Workflow Steps**
1. **{User Role 1} does**: {action}
   - System: {response}
2. **{User Role 2} receives**: {notification or data}
   - System: {what User Role 2 sees}
3. **{User Role 2} does**: {action}
   - System: {response}
4. **{User Role 1} receives**: {feedback or updated information}
...

**5.4 Data Exchanged**
{List all data that flows between users in this scenario}

**5.5 Clinical Safety Considerations**
{Any safety-critical aspects of this scenario}

---

**SCENARIO 2**: {Another multi-role scenario}

[Repeat structure]

---

### 6. WORKFLOW PAIN POINTS & REQUIREMENTS IMPLICATIONS

**6.1 Identified Pain Points**
Based on workflows, identify potential user frustrations:
1. **Pain Point**: {e.g., "Patient must re-enter same information multiple times"}
   - **User Impact**: {frustration, abandonment risk}
   - **Requirements Implication**: {e.g., "System shall pre-populate fields from prior entries"}

2. **Pain Point**: {e.g., "Physician has no way to quickly identify patients needing attention"}
   - **User Impact**: {clinical risk, workflow inefficiency}
   - **Requirements Implication**: {e.g., "System shall provide dashboard with patient risk stratification"}

[Continue for all identified pain points]

**6.2 Workflow Optimization Opportunities**
Identify areas where product can streamline workflows:
1. **Opportunity**: {e.g., "Automate patient reminders"}
   - **Current State**: {manual process or not done}
   - **Optimized State**: {automated, reducing burden}
   - **Requirements Implication**: {specific requirement to enable this}

[Continue for other opportunities]

---

### 7. WORKFLOW METRICS & ANALYTICS

**7.1 Workflow Completion Metrics**
For each key workflow, define how success will be measured:
- **{Workflow Name}**:
  - **Completion Rate**: {target percentage, e.g., â‰¥80% of users complete workflow}
  - **Time to Complete**: {target duration, e.g., â‰¤10 minutes}
  - **Error Rate**: {target, e.g., <5% of users encounter errors}
  - **Drop-off Point**: {where do users abandon? track and optimize}

**7.2 User Engagement Metrics**
- **Session Duration**: {target average session length}
- **Return Rate**: {percentage of users who return within X days}
- **Task Success Rate**: {percentage of tasks completed successfully}

---

### 8. ACCESSIBILITY & INCLUSIVITY CONSIDERATIONS

**8.1 Accessibility Needs by User Role**
- **{User Role}**: 
  - **Visual**: {e.g., screen reader support for visually impaired}
  - **Motor**: {e.g., voice input for users with limited dexterity}
  - **Cognitive**: {e.g., simple language for users with cognitive impairment}
  - **Auditory**: {e.g., captions for any audio content}

**8.2 Language & Cultural Considerations**
- **Languages Supported**: {English, Spanish, etc.}
- **Cultural Adaptations**: {any culturally-specific content or workflows}
- **Health Literacy**: {target reading level, e.g., 8th grade}

---

**OUTPUT FORMAT**:
- Document length: 6-10 pages
- Use workflow diagrams (can be simple text-based flowcharts if visual tools not available)
- Include user quotes or personas to make roles vivid
- Highlight critical paths and safety-sensitive workflows
- Note any assumptions about user behavior

**QUALITY STANDARDS**:
- All user roles comprehensively identified
- Workflows reflect real-world clinical practice
- Edge cases and error scenarios documented
- Pain points and optimization opportunities identified
- Accessibility needs considered for all user roles
- Workflows are detailed enough to drive requirements in next phase

**CRITICAL REMINDERS**:
- Workflows should reflect ACTUAL clinical practice, not idealized versions
- Pay special attention to workflows involving clinical decision-making (safety-critical)
- Document assumptions about user behavior and technology access
- Consider workflows for atypical users (e.g., very high or very low digital literacy)
```

---

#### **STEP 1.3: Establish Regulatory & Compliance Context (2-3 hours)**

**Objective**: Determine which regulatory requirements, standards, and compliance frameworks apply to the product.

**Persona**: P05_REGDIR (Lead), P09_QARA

**Prerequisites**:
- Product Vision & Clinical Context Document (Step 1.1)
- Understanding of intended use and risk level

**Process**:

1. **Confirm Regulatory Classification** (45 minutes)
   - FDA device classification (Class I/II/III or exempt)
   - International classifications (CE Mark, MDSAP)
   - Software classification (MDDS, CDS, SaMD)

2. **Execute PROMPT 1.3.1: Regulatory & Compliance Framework Determination** (90 minutes)

3. **Identify Applicable Standards & Guidance** (30 minutes)
   - Design control standards (21 CFR 820.30, ISO 13485, IEC 62304)
   - Clinical standards (FHIR, HL7, clinical data models)
   - Privacy/security (HIPAA, GDPR, HITRUST)
   - Usability (IEC 62366 human factors)

4. **Document Regulatory Strategy** (30 minutes)
   - Submission requirements
   - Required documentation
   - Testing and validation needs
   - Timeline and milestones

**Deliverable**: Regulatory & Compliance Context Document (5-7 pages)

**Quality Check**:
âœ… Regulatory classification confirmed  
âœ… All applicable standards identified  
âœ… Compliance requirements clear  
âœ… Regulatory strategy documented  
âœ… Requirements implications noted  

---

**PROMPT 1.3.1: Regulatory & Compliance Framework Determination**

```markdown
**ROLE**: You are P05_REGDIR (Director of Regulatory Affairs) working with P09_QARA (Quality Assurance / Regulatory Affairs Engineer) to establish the regulatory and compliance framework for a new digital health product.

**TASK**: Create a comprehensive Regulatory & Compliance Context document that identifies all applicable regulations, standards, and compliance requirements that will drive product requirements.

**CONTEXT**:
You are determining regulatory requirements for: {product_name_from_step_1.1}

**INPUT INFORMATION**:

**Product Overview** (from Step 1.1):
- **Intended Use**: {paste_intended_use_statement}
- **Product Type**: {DTx / SaMD / medical device / etc.}
- **Target Markets**: {US / EU / other}
- **Risk Level**: {preliminary assessment: low / moderate / high}

**INSTRUCTIONS**:

Generate a comprehensive Regulatory & Compliance Context document with the following structure:

---

### 1. REGULATORY CLASSIFICATION

**1.1 FDA Classification (US Market)**

**Device Classification Determination**:
Based on intended use {paste_intended_use_statement}, analyze:

**Question 1: Is this a medical device per FDA definition (21 CFR 820.3)?**
- Definition: Device intended for diagnosis, cure, mitigation, treatment, or prevention of disease
- **Answer**: {YES / NO}
- **Rationale**: {explain why}

**If YES â†’ Device Classification**:
- **Proposed Classification**: {Class I / Class II / Class III}
- **Product Code**: {if known, e.g., DQK for Software, Cardiovascular}
- **Regulation Number**: {e.g., 21 CFR 870.2340}
- **Device Panel**: {e.g., Cardiovascular, Neurology, General Hospital}
- **Classification Rationale**: {why this class? cite precedent or guidance}

**Exemption Status**:
- **Is device exempt from 510(k)?**: {YES / NO}
- **Is device exempt from design controls (21 CFR 820.30)?**: {YES / NO}
- **Is device exempt from cGMP (21 CFR 820)?**: {YES / NO}

**Special Classification Considerations**:

**Clinical Decision Support (CDS) Software**: 
- Does product qualify for CDS exemption per Section 520(o) of FD&C Act?
  - [ ] Criterion 1: Not intended for acquisition, processing, or analysis of medical images or signals
  - [ ] Criterion 2: Displays, analyzes, or prints medical information
  - [ ] Criterion 3: Supports or provides recommendations to HCP about diagnosis, treatment, prevention
  - [ ] Criterion 4: Enables HCP to independently review basis for recommendations
- **CDS Exemption Status**: {QUALIFIES / DOES NOT QUALIFY}
- **Rationale**: {explain}

**Software Type**:
- [ ] Software as a Medical Device (SaMD)
- [ ] Software in a Medical Device (SiMD)
- [ ] Medical Device Data System (MDDS) - 21 CFR 880.6310
- [ ] Not a medical device

**1.2 International Classifications**

**EU MDR (Medical Device Regulation 2017/745)**:
- **Classification Rule Applied**: {Rule 11 for software, or other applicable rule}
- **Proposed Class**: {Class I / IIa / IIb / III}
- **Rationale**: {based on MDR Annex VIII classification rules}
- **Notified Body Required?**: {YES / NO}

**IMDRF SaMD Risk Categorization** (if applicable):
- **Healthcare Situation Significance**: {Critical / Serious / Non-Serious}
- **State of Healthcare Situation**: {Treat/Diagnose / Drive Clinical Management / Inform Clinical Management}
- **IMDRF Risk Category**: {I / II / III / IV}

**Other Markets** (if applicable):
- **Canada (Health Canada)**: {Class I / II / III / IV}
- **Australia (TGA)**: {Class I / IIa / IIb / III}
- **Japan (PMDA)**: {classification if applicable}

---

### 2. APPLICABLE REGULATIONS & STANDARDS

**2.1 FDA Regulations (US)**

**21 CFR Part 820: Quality System Regulation (QSR)**:
- **Â§820.30 Design Controls**: {REQUIRED / EXEMPT}
  - If REQUIRED, implications for requirements documentation:
    - Â§820.30(c): Design input must document user needs, intended uses, performance requirements
    - Â§820.30(d): Design output must satisfy design input requirements
    - Â§820.30(f): Design verification must confirm outputs meet inputs
    - Â§820.30(g): Design validation must confirm device meets user needs

**21 CFR Part 11: Electronic Records & Signatures** (if applicable):
- **Applicability**: {APPLIES / DOES NOT APPLY}
- **Rationale**: {does product create/manage electronic records submitted to FDA?}

**21 CFR Part 312: IND Requirements** (if clinical investigation required):
- **Clinical Investigation Required?**: {YES / NO}
- **IND Exemption Status**: {Exempt / Significant Risk / Non-Significant Risk}

**FDA Guidance Documents Applicable**:
1. **{Guidance Title}** (Year)
   - Applicability: {how this guidance applies to product}
   - Key Requirements: {main requirements from guidance}
2. **{Another Guidance}**
[Continue for all applicable guidance]

Examples of potentially relevant guidance:
- "Content of Premarket Submissions for Device Software Functions" (2023)
- "Clinical Decision Support Software" (2022)
- "Policy for Device Software Functions and Mobile Medical Applications" (2022)
- "Cybersecurity in Medical Devices: Quality System Considerations" (2022)
- "Human Factors and Usability Engineering for Medical Devices" (2022)

**2.2 International Standards**

**ISO 13485:2016 - Medical Devices Quality Management System**:
- **Applicability**: {REQUIRED for all medical devices}
- **Key Clauses for Requirements**:
  - Clause 7.3.2: Design and development planning
  - Clause 7.3.3: Design and development inputs
  - Clause 7.3.4: Design and development outputs
  - Clause 7.3.5: Design and development review
  - Clause 7.3.6: Design and development verification
  - Clause 7.3.7: Design and development validation

**IEC 62304:2006/AMD1:2015 - Medical Device Software Lifecycle Processes**:
- **Applicability**: {REQUIRED for SaMD and SiMD}
- **Software Safety Classification**: {Class A / B / C}
  - Class A: No injury or damage to health
  - Class B: Non-serious injury possible
  - Class C: Death or serious injury possible
- **Key Requirements**:
  - Section 5.2: Software requirements specification
  - Section 5.3: Software architecture
  - Section 5.5: Software integration and testing
  - Section 5.6: Software system testing
  - Section 8: Software risk management

**IEC 62366-1:2015 - Usability Engineering for Medical Devices**:
- **Applicability**: {REQUIRED for devices with user interface}
- **Key Requirements**:
  - Clause 5.1: Identify users, use environments, UI characteristics
  - Clause 5.3: Identify user interface related use scenarios
  - Clause 5.7: Establish user interface specification
  - Clause 5.8: Establish use-related risk control measures
  - Formative and summative usability testing required

**ISO 14971:2019 - Risk Management for Medical Devices**:
- **Applicability**: {REQUIRED for all medical devices}
- **Key Requirements for Requirements Phase**:
  - Clause 5.3: Identify intended use and reasonably foreseeable misuse
  - Clause 5.4: Identify characteristics related to safety
  - Clause 7: Risk control measures must be implemented in design
  - Risk control measures â†’ requirements

**ISO 27001:2013 - Information Security Management** (if PHI/PII handled):
- **Applicability**: {APPLIES if product handles sensitive data}
- **Key Requirements**: {Annex A controls applicable}

**IEC 82304-1:2016 - Health Software (non-device software)**:
- **Applicability**: {if not a medical device but health-related}
- **Key Requirements**: {safety, security, data protection}

**2.3 Data Privacy & Security Regulations**

**HIPAA (Health Insurance Portability and Accountability Act) - US**:
- **Applicability**: {APPLIES if product creates, receives, maintains, or transmits PHI}
- **Covered Entity or Business Associate?**: {determination}
- **Key Requirements**:
  - HIPAA Privacy Rule (45 CFR Part 160, Part 164 Subparts A & E)
  - HIPAA Security Rule (45 CFR Part 164 Subparts A & C)
    - Administrative safeguards
    - Physical safeguards
    - Technical safeguards
  - Breach Notification Rule (45 CFR Part 164 Subpart D)

**GDPR (General Data Protection Regulation) - EU**:
- **Applicability**: {APPLIES if product processes personal data of EU residents}
- **Data Controller or Processor?**: {determination}
- **Key Requirements**:
  - Lawful basis for processing (Art. 6)
  - Data subject rights (Art. 15-22)
  - Data protection by design (Art. 25)
  - Data breach notification (Art. 33-34)
  - Privacy impact assessment if high risk (Art. 35)

**CCPA/CPRA (California Consumer Privacy Act) - US**:
- **Applicability**: {if selling to California consumers}

**HITRUST CSF (Health Information Trust Alliance Common Security Framework)**:
- **Applicability**: {Optional but often required by payers/health systems}
- **Certification Target**: {HITRUST Essentials (E1) / HITRUST Implemented (i1) / HITRUST Risk-based, 2-year (r2)}

**2.4 Interoperability & Clinical Data Standards**

**HL7 FHIR (Fast Healthcare Interoperability Resources)**:
- **Applicability**: {if EHR integration required}
- **FHIR Version**: {R4, R5}
- **Relevant Profiles**: {e.g., US Core, SMART on FHIR}

**HL7 V2 Messaging**:
- **Applicability**: {if legacy EHR integration}

**DICOM (Digital Imaging and Communications in Medicine)**:
- **Applicability**: {if medical imaging involved}

**2.5 Accessibility Standards**

**WCAG 2.1 (Web Content Accessibility Guidelines) - Level AA**:
- **Applicability**: {REQUIRED for patient-facing web apps}
- **Key Principles**: Perceivable, Operable, Understandable, Robust

**Section 508 of Rehabilitation Act (US)**:
- **Applicability**: {REQUIRED if selling to US government}

---

### 3. REGULATORY STRATEGY & PATHWAY

**3.1 US FDA Submission Pathway**

**Recommended Pathway**: {choose one}
- [ ] No submission required (not a device or Class I exempt)
- [ ] 510(k) - Premarket Notification
- [ ] De Novo - Request for Classification
- [ ] PMA - Premarket Approval
- [ ] Humanitarian Device Exemption (HDE)

**Rationale**: {why this pathway? cite precedent or guidance}

**Pre-Submission Meeting**: {RECOMMENDED / NOT NEEDED}
- If recommended, timing: {e.g., "Before completing verification testing"}
- Topics to discuss: {e.g., "Clinical validation approach, endpoint selection"}

**Special Programs** (if applicable):
- [ ] Breakthrough Devices Program
- [ ] FDA's Digital Health Pre-Cert Program (if participant)
- [ ] De Novo pathway with Special Controls

**Estimated Timeline**:
- Requirements complete: {date}
- Design complete: {date}
- Verification complete: {date}
- Validation complete: {date}
- Submission: {date}
- FDA review: {estimate 90-180 days for 510(k), 12-18 mo for De Novo}
- Clearance/Approval: {target date}

**3.2 EU Conformity Assessment**

**Notified Body Required?**: {YES / NO}
- If YES, estimated timeline: {6-12 months for Class IIa, 12-18 months for IIb/III}

**CE Marking Strategy**: {self-certification / Notified Body}

**UK CA Marking** (if selling to UK post-Brexit): {strategy}

**3.3 Other Markets**

{Document strategy for Canada, Australia, Japan, other markets if applicable}

---

### 4. REQUIREMENTS IMPLICATIONS

**4.1 Design Control Documentation Required**

Per 21 CFR 820.30 and ISO 13485, the following documentation MUST be produced:

1. **Design Input** (This use case - UC-26)
   - Clinical Requirements Specification (CRS)
   - User needs documentation
   - Intended use and indications for use
   - Performance requirements (clinical, technical, usability)
   - Regulatory requirements applicable to design

2. **Design Output**
   - Detailed design specifications
   - Software architecture (per IEC 62304)
   - User interface specifications
   - Data model and database schema
   - Algorithm specifications (if applicable)

3. **Verification & Validation Plans**
   - Design verification protocol (testing that outputs meet inputs)
   - Design validation protocol (testing that device meets user needs)
   - Usability testing protocol (per IEC 62366)
   - Clinical validation protocol (if applicable)

4. **Risk Management File** (per ISO 14971)
   - Hazard analysis
   - Risk assessment and evaluation
   - Risk control measures
   - Residual risk evaluation

5. **Traceability**
   - Requirements Traceability Matrix (RTM)
   - Risk-Requirements linkage
   - Test case-Requirements linkage

**4.2 Specific Requirement Types Mandated by Regulations**

Based on applicable regulations, the Clinical Requirements Specification MUST include:

**Functional Requirements**:
- All clinical functions the device performs
- Data inputs and outputs
- Clinical decision logic (if applicable)
- User interactions and workflows

**Performance Requirements**:
- Clinical accuracy/performance criteria (e.g., sensitivity, specificity)
- Technical performance (response time, uptime)
- Scalability requirements

**Safety Requirements**:
- Risk control measures (from risk analysis)
- Alarm/alert requirements (if applicable)
- Error handling and graceful degradation
- Data validation rules to prevent unsafe inputs

**Security Requirements** (if HIPAA/GDPR applicable):
- Authentication and authorization
- Data encryption (at rest and in transit)
- Audit logging
- Breach detection

**Usability Requirements** (per IEC 62366):
- Use scenarios and user tasks
- Use-related hazards and risk controls
- Usability testing success criteria

**Interoperability Requirements** (if EHR integration):
- FHIR resources supported
- HL7 message types
- API specifications

**Data Privacy Requirements** (if PHI/PII):
- Consent management
- Data subject rights (access, deletion, portability per GDPR)
- Data retention and disposal

---

### 5. COMPLIANCE VERIFICATION STRATEGY

**5.1 Regulatory Checkpoints in Development**

| Development Phase | Regulatory Checkpoint | Responsible Party |
|-------------------|----------------------|-------------------|
| Requirements Complete | Design Input Review & Approval | P05_REGDIR, P09_QARA |
| Design Complete | Design Output Review & Approval | P09_QARA |
| Development Complete | Design Verification Testing | Quality/Test team |
| Pre-Launch | Design Validation Testing | P02_VPCLIN, P09_QARA |
| Pre-Submission | Design History File (DHF) Review | P05_REGDIR, P09_QARA |
| Post-Launch | Post-Market Surveillance | P01_CMO, P05_REGDIR |

**5.2 Audits & Inspections Preparation**

**Internal Audits**: {frequency, e.g., quarterly during development}

**External Audits**:
- ISO 13485 certification audit: {timing}
- FDA inspection readiness: {when to prepare}

**Key Documentation for Audits**:
- Design History File (DHF)
- Device Master Record (DMR)
- Requirements Traceability Matrix
- Risk Management File
- Verification & Validation Reports

---

### 6. REGULATORY RISKS & MITIGATION

**6.1 Top Regulatory Risks**

| Risk | Probability | Impact | Mitigation Strategy |
|------|-------------|--------|---------------------|
| {e.g., FDA questions clinical validation approach} | {H/M/L} | {H/M/L} | {e.g., Pre-Sub meeting to align on approach} |
| {e.g., Requirements not traceable} | {M} | {H} | {Implement robust traceability from start} |
| {e.g., HIPAA violation discovered} | {L} | {H} | {Privacy by design, early security audit} |
| ... | ... | ... | ... |

**6.2 Regulatory Contingency Plans**

**If FDA issues Not Substantially Equivalent (NSE) decision for 510(k)**:
- Option 1: {e.g., Pivot to De Novo pathway}
- Option 2: {e.g., Conduct additional clinical testing}
- Timeline impact: {estimate}

**If Notified Body raises major non-conformity**:
- Remediation strategy: {approach}
- Timeline impact: {estimate}

---

### 7. REGULATORY INTELLIGENCE & PRECEDENT

**7.1 Similar Devices Cleared/Approved**

| Device Name | Company | FDA #| Indication | Pathway | Year | Relevance |
|-------------|---------|------|------------|---------|------|-----------|
| {e.g., reSET} | Pear Therapeutics | K172133 | Substance Use Disorder | De Novo | 2017 | Similar DTx, outcome measures |
| ... | ... | ... | ... | ... | ... | ... |

**7.2 Relevant FDA Warning Letters / 483s**

{List any relevant enforcement actions that provide lessons learned}

---

**OUTPUT FORMAT**:
- Document length: 7-12 pages
- Include regulatory citations for all claims
- Provide FDA/EMA guidance document numbers
- Include timeline tables
- Highlight critical regulatory requirements that impact product requirements

**QUALITY STANDARDS**:
- Regulatory classification clearly determined with rationale
- All applicable regulations and standards identified
- Requirements implications explicitly stated
- Regulatory strategy documented with realistic timelines
- Risks identified with mitigation strategies

**CRITICAL REMINDERS**:
- Regulatory classification drives ALL downstream requirements
- Failure to identify applicable standards early = costly rework later
- Design Control documentation is legally required for most medical devices
- Requirements Traceability Matrix is not optional - it's mandated by 21 CFR 820.30(i)
```

---

[Document continues with PHASE 2, PHASE 3, PHASE 4, remaining prompts, examples, metrics, troubleshooting, and appendices...]

---

## DOCUMENT STATUS

**Version**: 1.0 Complete Edition  
**Date**: October 11, 2025  
**Status**: Production-Ready - Awaiting Expert Validation

**Completeness**:
- âœ… Executive Summary complete
- âœ… Business Context & Value Proposition complete
- âœ… Persona Definitions complete (6 personas)
- âœ… Workflow Overview complete
- âœ… Phase 1 Implementation Guide complete (3 steps with detailed prompts)
- âš ï¸ Phase 2-4 outlined (to be fully detailed in subsequent iterations)
- âš ï¸ Complete Prompt Suite (15 prompts total - 3 fully detailed, 12 outlined)
- âš ï¸ Examples & Case Studies (to be added)
- âš ï¸ How-To Guide (to be added)
- âš ï¸ Success Metrics (to be added)
- âš ï¸ Troubleshooting & FAQs (to be added)
- âš ï¸ Appendices (to be added)

**Next Steps for Full Implementation**:
1. Complete Phase 2-4 detailed step-by-step guides
2. Develop all 15 prompts to full detail
3. Add 2-3 comprehensive case study examples
4. Create requirements template library
5. Develop training materials
6. Expert validation by P01_CMO, P06_VPPRODUCT, P05_REGDIR

---

## ACKNOWLEDGMENTS

**Framework**: PROMPTSâ„¢ (Purpose-driven Robust Outcomes Master Prompting Toolkit & Suites)  
**Suite**: FORGEâ„¢ (Foundation Optimization Regulatory Guidelines Engineering)

**Document prepared by**: Life Sciences Intelligence Prompt Library (LSIPL) Team  
**Expert Reviewers**: [To be added after validation]

**Related Documents**:
- UC-10: Clinical Trial Protocol Development
- UC-13: Pharmacovigilance & ICSR Processing
- UC-14: FDA Digital Health Pre-Certification Readiness
- Digital Health Prompt Library v1.0

---

**END OF UC-26 CLINICAL REQUIREMENTS DOCUMENTATION - PHASE 1**

---

**For questions, feedback, or implementation support, contact the Digital Health Product Development Team.**

**Document License**: This document is provided for use within the organization. External distribution requires approval.
